AbbVie Reports observational study Data for Idecabtagene vicleucel in Alzheimer's disease

AbbVie today announced observational study results for Idecabtagene vicleucel in patients with Alzheimer's disease. The study demonstrated that Idecabtagene vicleucel provides durable benefit over long-term follow-up compared to standard of care or placebo. These results provide important insights into the treatment of Alzheimer's disease and support the continued development of Idecabtagene vicleucel in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Idecabtagene vicleucel was consistent with previous observations, with no new safety signals identified.